PMID- 36892260
OWN - NLM
STAT- MEDLINE
DCOM- 20230406
LR  - 20230406
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Dec
TI  - Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory 
      Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective 
      studies.
PG  - 2181749
LID - 10.1080/16078454.2023.2181749 [doi]
AB  - BACKGROUND: Inhibitors of programmed cell death protein 1 (PD-1) and programmed 
      cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and 
      refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety 
      and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis. 
      METHODS: Databases and the Clinical Registration Platforms have been 
      systematically searched for related studies by March 2022. For safety analysis, 
      the incidence and exhibition of any grade and grade 3 or higher adverse effects 
      (AEs) were evaluated. Besides, severe AEs (SAEs), treatment-related deaths, and 
      AEs leading to treatment discontinuation were summarized. The overall response 
      rate (ORR), complete response (CR) rate, partial response (PR) rate, 
      progression-free survival (PFS), overall survival (OS), and duration of response 
      (DOR) were calculated for efficacy analysis. All processes were implemented 
      mainly through the package Meta and MetaSurv of software R 4.1.2. RESULTS: 
      Overall 20 studies and 1440 patients were enrolled. The pooled incidence of any 
      grade and grade 3 or higher AEs were 92% and 26%, respectively. The pooled ORR, 
      CR rate and PR rate were 79%, 44% and 34%, respectively. The most common AEs were 
      neuropathy (29%), nausea (27%), pyrexia (26%), and leukopenia (25%), and the most 
      common grade 3 or higher AEs included leukopenia (10%), infusion reaction (8%), 
      weight gain (3%), and neutropenia (2.7%). In survival analysis, pembrolizumab 
      monotherapy appeared to perform better compared to nivolumab monotherapy. 
      CONCLUSIONS: PD-1/PD-L1 inhibitors show promising efficacy and tolerable AEs in 
      the treatment of R/R HL.
FAU - Sun, Chenxi
AU  - Sun C
AUID- ORCID: 0000-0002-8139-2979
AD  - The Second Hospital of Shandong University, Jinan, Shandong, People's Republic of 
      China.
FAU - Chen, Huixian
AU  - Chen H
AUID- ORCID: 0000-0003-2808-5360
AD  - Center for Clinical Research, The Affiliated Hospital of Qingdao University, 
      Qingdao, People's Republic of China.
FAU - Wang, Yongjing
AU  - Wang Y
AD  - Department of Hematology, The Second Hospital of Shandong University, Jinan, 
      Shandong, People's Republic of China.
AD  - Institute of Biotherapy for Hematological Malignancies, Shandong University, 
      Jinan, Shandong, People's Republic of China.
AD  - Shandong University-Karolinska Institute Collaboration Laboratory for Stem Cell 
      Research, Jinan, Shandong, People's Republic of China.
FAU - Zheng, Chengyun
AU  - Zheng C
AUID- ORCID: 0000-0001-6260-297X
AD  - Department of Hematology, The Second Hospital of Shandong University, Jinan, 
      Shandong, People's Republic of China.
AD  - Institute of Biotherapy for Hematological Malignancies, Shandong University, 
      Jinan, Shandong, People's Republic of China.
AD  - Shandong University-Karolinska Institute Collaboration Laboratory for Stem Cell 
      Research, Jinan, Shandong, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Humans
MH  - B7-H1 Antigen
MH  - *Hodgkin Disease/drug therapy
MH  - *Immune Checkpoint Inhibitors/adverse effects/therapeutic use
MH  - Leukopenia/chemically induced
MH  - Programmed Cell Death 1 Receptor
MH  - Prospective Studies
OTO - NOTNLM
OT  - PD-1/PD-L1 inhibitors
OT  - camrelizumab
OT  - efficacy
OT  - meta-analysis
OT  - nivolumab
OT  - pembrolizumab
OT  - relapsed and refractory Hodgkin's lymphoma
OT  - safety
EDAT- 2023/03/10 06:00
MHDA- 2023/03/11 06:00
CRDT- 2023/03/09 08:43
PHST- 2023/03/09 08:43 [entrez]
PHST- 2023/03/10 06:00 [pubmed]
PHST- 2023/03/11 06:00 [medline]
AID - 10.1080/16078454.2023.2181749 [doi]
PST - ppublish
SO  - Hematology. 2023 Dec;28(1):2181749. doi: 10.1080/16078454.2023.2181749.